Table 3.

Potential arrhythmic adverse effects of antineoplastic drugs

Antineoplastic drugs	Potential arrhythmic adverse effect
Anthracyclines Doxorubicin Daunorubicin Epirubicin Idarubicin Mitoxantrone	Arrhythmias
Alkylating agents     Melphalan	Arrhythmias
Inibitori delle tirosin chinasi Axitinib Cabozantinib Cetuximab Crizotinib Dabrafenib Dasatinib Imatinib	Bradyarrhythmias QT interval prolongation Atrial fibrillation
Osimertinib	QT interval prolongation Atrial fibrillation
Pazopanib	Bradyarrhythmias
Trametinib	Bradyarrhythmias QT interval prolongation
Vandetanib	QT interval prolongation
Vemurafenib	QT interval prolongation
Immune checkpoint inhibitors Cemiplimab Nivolumab Pembrolizumab	Myocarditis Arrhythmias Cardiac sudden death
PD-L1 inhibitors Atezolizumab Avelumab Durvalumab
CTLA-4 inhibitors Ipilimumab
Histone deacetylase inhibitors Belinostat Vorinostat	QT interval prolongation
Terapia endocrina	Modulatori selettivi dei recettori oestrogenici Tamoxifen • Toremifen	QT interval prolongation
Endocrine therapy selective modulators of oestrogen receptors Tamoxifen Toremifene	Tachycardias Arrhythmias
Ribociclib	QT interval prolongation
Arsenic dioxide	QT interval prolongation